Recent News

• 03.26.2026 - Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
• 03.19.2026 - Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
• 03.12.2026 - Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
• 02.25.2026 - Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
• 01.22.2026 - Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
• 01.21.2026 - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Recent Filings

• 03.26.2026 - 8-K Current report
• 03.12.2026 - 8-K Current report
• 03.12.2026 - EX-99.1 EX-99.1
• 03.12.2026 - 8-K Current report
• 03.12.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2026 - RW Registration Withdrawal Request
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.13.2026 - 8-K Current report
• 01.22.2026 - EX-99.1 EX-99.1